Patients / public:
1 (1 votes)healthcare Prof:
Jennerex, Inc., a private clinical phase Biotherapeutics company focused on the development and marketing of first-in-class targeted Oncolytic products for cancer and transgene (NYSE Euronext Paris: FR0005175080), a bio pharmaceutical company specialized in the development of Immunotherapeutic products, reported interim results from phase 1 dose escalation clinical studies show, that management of JX-594 targets tumor vascular system. Directly targeting and replicate within tumor vasculature, JX-594 disrupts the blood supply to the solid tumors to the destruction of cancer. Data were reported annual meeting of the American Association for cancer research (AACR) in Orlando, Florida in a poster presentation at the 102nd.
"In addition to targeted, infect and stimulate cancer cells to destroy and a specific immune response against remaining cancer cells, shows the analysis on AACR JX-594 critical third mechanism of action of the disorder of the blood supply to tumors," said David H. KirnM.d, President and Chief Executive Officer of Jennerex.
"It is more important, these data show that vascular system can attack both intravenously and intratumoral injections of JX-594 effective tumor." These results further show that JX-594 therapeutic benefits for a variety of solid tumors such as liver, colorectal and other cancers, may "Philippe Archinard, Chairman and Chief Executive Officer of transgene added."
Twenty-three patients were 1 dose escalation clinical trial of intravenous JX-594 advanced in the phase, treat treatment refraktärer solid tumors are registered. Tumor biopsies, evaluated by immunohistochemical analysis showed that JX-594 caused the vascular system of tumors intravenously given the blood supply to the tumor be infected too disturbed. In addition was magnetic resonance imaging of tumor to evaluate perfusion used in another study of patients with primary liver cancer, which received intratumoral injections of JX-594, acute decline. Only five days after the treatment with JX-594 the tumor has been a significant decrease in perfusion observed result in acute tumor destruction. Vascular shutdown on tumor tissue was limited, and no significant changes were observed in normal tissue perfusion. At later dates, Choi reported (necrotic) answers in these same patients. The studies are conducted at sites in South Korea and North America.
About JX-594
JX-594 is the selective target, a proprietary, engineered Oncolytic virus and destroy cancer cells to. JX-594 was designed to attack to cancer by three different mechanisms of action: the destruction of cancer cells by viral replication, the reduction of the blood supply to tumors by vascular targeting and destruction, and the stimulation of the body's own immune response against the cancer cells, i.e. active immunotherapy. Phase 1 and phase 2 studies in several cancer types so far have shown that JX-594, either directly in tumors or systemically, induces tumor shrinkage and/or necrosis and is well tolerated by patients. Objective tumor response has been demonstrated in various cancers, including liver, colon, kidney, lung and melanoma.
Transgene contains an exclusive license to develop and commercialize JX-594 in Europe and neighbouring countries. One of an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharma Ltd. Green Cross Corporation, a leader in the development, manufacture and marketing of viral vaccines and other biological products, exclusive license to develop and commercialize JX-594 in China.
Source: Jennerex, Inc
Posts
0 comments: on "Jennerex and transgenic compatible presentation of phase 1 data demonstrates that JX-594 administration targets tumor vascular system"
Post a Comment